Aprea Therapeutics (APRE)

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

https://www.aprea.com

• YTD Return

  APRE-35.96%
  S&P 500+24.05%

• 1-Year Return

  APRE-20.16%
  S&P 500+31.08%

• 3-Year Return

  APRE-96.56%
  S&P 500+25.95%

• 5-Year Return

  APRE-99.50%
  S&P 500+89.64%